Summary:
Epstein-Barr virus belongs to the herpesvirus family and, like other viruses, may cause only mild symptoms after exposure. The majority of people are exposed to the primary infection during their adulthood. The virus in the infected B cells remains latent while immune functions remain competent. However, in primary or secondary (acquired) immunodeficiency states, the latent EBVinfected B cells may undergo uncontrolled proliferation and transformation into a EBV-associated B cell lymphoproliferative disorder, a life-threatening complication.
Bone marrow transplantation provides a life-saving therapy for a variety of hematologic and non-hematologic diseases. 1 In bone marrow transplant recipients, manipulation of the marrow graft, infection, graft-versus-host disease (GVHD), and/or usage of immunosuppressive agents all contribute to delay in immune reconstitution. The incidence of EBV-LPD has been reported to be between 5 and 39% in solid organ transplant recipients. [2] [3] [4] EBV-LPD following autologous BMT is rare, 5, 6 and the incidence of EBV-LPD in HLA-identical sibling bone marrow transplants is generally less than 1%. 7 Recently, several reports [8] [9] [10] [11] [12] have identified risk factors in allogeneic transplants, which are associated with an increased incidence of EBV-LPD. These risk factors include HLA disparity, depletion of the donor marrow graft with T cell-specific monoclonal antibodies (MAb), use of antithymocyte globulin in vivo, and severe GVHD.
Increasing numbers of BMT are being performed using alternative donors and manipulated grafts. There has not been much reported focus on the incidence of EBV-LPD on these high-risk patients group. We retrospectively examined EBV-LPD in a series of 318 patients who underwent partially mismatched related donor bone marrow transplants at the Division of Transplantation Medicine in the University of South Carolina. This study represents the largest series describing the incidence of EBV-LPD following PMRD bone marrow transplants with T cell-depleted grafts from a single institution. This descriptive report is focused on EBV-LPD clinical characteristics, relationship with risk factors (ie T cell depletion methods, HLA disparity, ATG doses, and GVHD), and treatment modalities and outcomes following PMRD BMT.
Patients and methods

Patients
Between February 1993 and June 1998, a total of 315 PMRD bone marrow transplants were performed at Palmetto Richland Memorial Hospital, University of South Carolina. Six patients received two separate transplants, giving a total of 321 transplants. Three patients who died prior to transplant were not evaluable for EBV-LPD because they did not receive their graft and were not included in this analysis. All potential recipients and donors received complete evaluations and gave informed consent approved by the Institutional Review Board prior to their PMRD BMT procedures.
Donors
Immediate family members were HLA typed by serologic test. Donor selection was based on the degree of HLA disparity, age, viral serology, sex and general health condition.
Transplant procedures
The conditioning regimen included etoposide, cytosine arabinoside, cyclophosphamide, methylprednisolone with or without total body irradiation (TBI). Fifty-nine percent of patients also received three extra doses of ATG during conditioning. The majority of patients (88.1%) received a TBIbased conditioning regimen. The dose of TBI ranged from 1332 cGy to 1500 cGy. Of them, 198 patients (62.3%) received 1410 cGy. All marrow grafts were ex vivo incubated with either T10B9 (30.2%) or OKT3 (69.8%) and complement for partial mature T cell depletion. 13, 14 In addition to cyclosporine A (CsA) and steroids, all patients received 12 doses of post-transplant ATG as part of GVHD prophylaxis. Patients with primary graft failure received a second graft. All patients were admitted in a single, isolated, HEPA filter room. Anti-microbial (bacterial, fungal and viral) agents were administered during the transplantation course. Post discharge, patients were followed in the BMT outpatient clinic until day +100 before they returned to their referring physicians. Patients were asked to return for further follow-up every 3 months during the first year post-BMT, every 6 months during the second year, and then yearly. Close communication was consistently maintained between referring physicians and the BMT team to ensure any potential complications were addressed.
Diagnosis of EBV-LPD
Review of clinical records identified 18 patients with EBV-LPD of whom seven were previously reported. 15, 16 When clinical suspicions of LPD were entertained, every effort was made to obtain a tissue biopsy for pathological confirmation of the diagnosis of EBV-LPD. Peripheral blood as well as biopsy tissue samples (whenever possible) were sent for flow cytometric analysis for the presence of abnormal cellular clonality. Chimerism status was determined from either peripheral blood or bone marrow specimens when available. Serial blood tests were also performed for the quantitative and qualitative detection of EBV by PCR. EBER/EBNA were not obtained. Every effort was made to carry out a post-mortem examination to accurately identify the cause of death.
Treatment and follow-up
Once the diagnosis of EBV-LPD was confirmed, aggressive therapy including withdrawal of immunosuppressive agents, antiviral, and other supportive care was immediately initiated. Response of EBV-LPD to treatment was monitored by serial clinical and/or radiological examinations. Complete response was defined as total resolution of symptoms/signs upon follow-up examination, and partial response was greater than 50% reduction in lesions.
Donor leukocyte infusion (DLI)
Donor blood was collected by venipuncture. Percentage of lymphocytes was determined by flow cytometry. The final product was calculated by CD3
+ dose per kg of recipient weight. Seventy-six (23.9%) patients received at least one DLI post BMT, of which 42 (55.3%) DLIs were given to prevent relapse, 21 (27.6%) to treat relapse, nine (11.8%) for the treatment of EBV-LPD, and four (5.3%) for other reasons.
Statistical methods
Patients were selected for inclusion in this study based on all PMRD transplants performed at Division of Transplantation Medicine, Palmetto Richland Memorial Hospital. Data were collected retrospectively on this cohort by chart review and by utilization of other data collected routinely and concurrently. Patients who received a second graft due to primary graft failure were censored for EBV-LPD on the date the second graft was infused. Patients with two transplants were censored for EBV-LPD for the first transplant on the date of the second transplant. Patients who died prior to transplant were excluded. Engraftment was defined as the first of 3 consecutive days that the white blood cell count exceeded 1000/l. The probability of developing EBV-LPD was estimated using the method of Kaplan and Meier. 17 The log-rank test was used to test for significance of differences between groups using time-tofailure data. Risk factors for development of EBV-LPD were dichotomized as follows: number of ATG doses (Ͻ15 vs у15), recipient/donor HLA disparity in the GVHD direction (Ͻ3 vs 3), T cell depletion methods (T10B9 vs OKT3), and severity of acute GVHD (grades 0-I vs grades II-IV).
Results
All patients
Two hundred and sixty-two patients (82.4%) were transplanted for leukemia. The majority (62.6%) of patients was male. Serology tests on recipients' EBV and CMV status revealed 88.1% and 56.9% positivity, respectively. The patients ranged in age from 1 to 58 (median 25) years. The donors ranged in age from 4 to 67 (median 29) years with the majority (84.3%) being positive for EBV, and they were evenly divided on CMV status. Table 1 illustrates the number of patients in each of the four risk factors (ie HLA mismatches in GVHD direction, T cell depletion methods, number of ATG doses and severity of GVHD) and the numbers of patient with EBV-LPD within each risk factor. The majority of patients (82.1%) was two to three HLA-antigens mismatched with their donors and received у15 doses of ATG. Only 61 (19.2%) patients developed grade II-IV acute GVHD.
EBV-LPD patients
There were 18 cases (10 males and eight females) of EBV-LPD diagnosed among the 318 PMRD transplants. The characteristics of these patients, transplanted for a variety of malignancies, are summarized in Table 2 . Median age was 21.5 years (range 4-53). Sixteen (88.9%) patients demonstrated antibodies to EBV prior to transplant and all but one donor was EBV positive. Half were CMV positive at the time of transplant while 10 patients received grafts from CMV-positive donors. All patients were mismatched in both the GVHD and rejection directions with their donors. All patients received ATG post graft infusion for GVHD prophylaxis while 13 (72.2%) patients also received ATG as part of their conditioning regimen.
All patients engrafted by day +19 (median 14 days). Six patients developed acute GVHD post transplant, ranging from grade I to grade III (grade III, n = 3), of whom all but one resolved with treatment (steroids, n = 6; ATG, n = 1; CsA, n = 2; and imuran, n = 1). One patient progressed to chronic GVHD. Only one patient was diagnosed with EBV-LPD at autopsy and three were diagnosed at their referral sites. The remainders of the diagnoses were made during their followup with us. The cell types were of donor origin when tested. The majority of patients presented with symptoms of lymphadenopathy and fever as shown in Table 3 . Median time to development of EBV-LPD was 137 days (range 48-617) post BMT. Fourteen (77.8%) cases occurred within the first 12 months. The estimated probability of developing EBV-LPD at 12 months was 0.08 (95% confidence interval (CI) 0.04-0.12). The remaining cases occurred between 12 and 24 months with an estimated probability at 60 months of 0.13 (95% CI: 0.07-0.19). No cases have been diagnosed to date beyond 24 months (Figure 1 ).
Treatment and outcomes
Once the diagnosis of EBV-LPD was made, appropriate therapies were immediately initiated. Treatment modalities (Table 3) included decreasing immunosuppressive agents (n = 16), high-dose acyclovir (n = 12), interferon-␣ (n = 10), immunoglobulins (IG) infusion (n = 12), radiation (n = 2), chemotherapy (n = 1), monoclonal anti-B cell antibody (Rituxan, IDEC Pharmaceuticals Corporation, San Diego, CA, USA) (n = 2) and donor leukocyte infusion (n = 9). Despite the combination of supportive care, EBV-LPD progressed rapidly in the majority of cases. Fifteen of the 18 EBV-LPD patients died, and eight deaths were directly attributed to EBV-LPD. Infections (Aspergillus and CMV), relapse, GVHD, and respiratory failure were the causes of death for the other seven patients. Of those, four responded to the EBV-LPD treatment. The time between the development of EBV-LPD and death from EBV was less than 1 month.
Eleven patients received at least one DLI (Table 4) ; nine of them received DLI as treatment for EBV-LPD. Three patients responded to DLI treatment (two with complete remission and one with partial remission), but only one is a long-term survivor. Of note, two patients who received DLI prophylactically to prevent relapse of their primary malignancy developed EBV-LPD. In both patients, EBV-LPD developed beyond 15 months (day +455 and day +569, respectively) after transplant. At the time of analysis, three of the EBV-LPD patients were alive without evidence of EBV-LPD.
Risk factors of EBV-LPD
Four known risk factors associated with EBV-LPD were examined. There was no significant difference in the probability of developing EBV-LPD by antigen mismatches in the GVHD direction (P = 0.772), T cell depletion methods (P = 0.416), total number of ATG doses (P = 0.385) and severity of acute GVHD (P = 0.320). In addition, the probability of developing EBV-LPD was not statistically different for CMV antibody positivity (either donor or recipient) compared to CMV antibody negativity (both donor and recipient) (P = 0.966). Conditioning regimen: 1, = total body irradiation, cyclophosphamide, cytosine arabinoside, etoposide, methylprednisolone; 2 = busulfan, cyclophosphamide, thiotepa, methylprednisolone; 3 = total body irradiation, cyclophosphamide, cytosine arabinoside, etoposide, methylprednisolone, antithymocyte globulin; 4 = total body irradiation, cyclophosphamide, cytosine arabinoside, methylprednisolone, antithymocyte globulin. AML = acute myeloid leukemia; CML = chronic myelogenous leukemia; NHL = non-Hodgkin's lymphoma; ALL = acute lymphoblastic leukemia; CLL = chronic lymphocytic leukemia; SAA = severe aplastic anemia; D = donor; R = recipient; Rej = rejection. Chemo = chemotherapy; CR = complete response; DLI = donor leukocyte infusion; IFN = interferon-alpha; Mab = monoclonal antibody (Rituxan); NR = no response; XRT = radiation; COD = cause of death; DAD = diffuse alveolar damage; HA = high-dose acyclovir; IG = intravenous immunoglobulin; NA = not available; PR = partial response.
Discussion
EBV-associated LPD is a well-documented complication in primarily and/or secondarily immunocompromised hosts. HLA-identical sibling BMT is reported to have a relatively low incidence of EBV-LPD. Gross et al 8 estimated 15.7% risk of LPD in HLA mismatched and T cell-depleted recipients at 6 months following transplant. In his analysis, 76 patients received mismatched and T cell-depleted grafts out of a total of 1542 allogeneic transplants. In a combined IBMTR and Seattle analysis comprising more than 18 000 transplants, Curtis et al 12 reported 22.3% cumulative incidence of LPD for patients with more than two known risk factors. Treatment PR NA = not applicable (patient received DLI prophylactically for disease relapse); NR = no response; CR = complete response; PR = partial response.
Using a mismatched family member as the donor makes timely BMT possible for patients from almost any ethnic group. All of the patients in this study were HLA mismatched with their donors. However, a three-antigen mismatch did not present a significantly greater risk of EBV-LPD than was seen in those patients transplanted with one or two antigen mismatched donor grafts (P = 0.772). The causes of EBV-LPD in patients who received HLA mismatched grafts is not clearly understood. Shapiro et al 7 suggested that chronic antigenic stimulation and activation of endogenous viruses were associated with EBV-LPD in the mismatched BMT setting.
Soybean agglutination with erythrocyte rosetting, elutriation, and monoclonal antibody with complement all have been used on marrow grafts in vitro to generate different degrees of T cell depletion. Each T cell depletion method (mechanical, physical or chemical) depletes different T cell sub-populations from the marrow graft. These methods have all been recognized as risk factors for the development of EBV-LPD. However, B cell depletion in addition to traditional T cell depletion methods has been suggested to prevent the EBV-induced LPD in mismatched allogeneic BMT. 18, 19 In our experience, using two different anti-T cell antibodies (OKT3-IgM and T10B9-IgG), similar degrees of T cell depletion with preservation of B cells was achieved. We did not observe any significant difference in EBV-LPD Bone Marrow Transplantation incidence between the two methods. It may be important in the future to study different T cell depletion methods, remaining T cell subsets (such as cytotoxic T cells) and B cell contents in the depleted graft, and to correlate with clinical immune reconstitution and the development of EBV-LPD post-BMT.
Post-transplant immunosuppression also contributes significantly to T cell dysfunction during the period following graft infusion. In our center, ATG (10 mg/kg/dose for 12 doses) was used for GVHD prophylaxis in all patients post transplant. Many patients also received ATG prior to marrow graft infusion in an effort to improve engraftment. ATG was also used as a second-line therapy for treating GVHD. In renal transplant patients, Iwatsuki et al 20 reported three out of seven patients who received more than 15 doses of ATG developed LPD compared to none out of eight who received less than 15 doses of ATG. The critical number of ATG doses administered and its relationship with the EBV-LPD in post-transplant recipients has not been carefully examined. However, we did not observe any significant difference in the incidence of EBV-LPD when using a similar parameter. It is possible that ATG is just one of many key steps in the pathogenesis of T cell dysfunction and the development of EBV-LPD. Therefore, no cause-and-effect relationship can be observed solely after different ATG doses.
GVHD can be a fatal complication in allogeneic BMT. Treatment of acute GVHD with immunosuppressive agents can further compromise a patient's recovery of immunoregulation. Studies 10, 12 have shown that severe acute GVHD and treatment with anti-CD3 in the setting of HLA disparity were important risk factors in EBV-LPD. In the current study, we reported a low risk of acute GVHD (the probability of grades II-IV was 0.19) which is comparable to the HLA-identical sibling transplant experience. Six patients who developed EBV-LPD had also developed GVHD. We also observed a trend towards a higher incidence of EBV-LPD in patients with grades II to IV GVHD than in those with no, or grade I GVHD (10% vs 4.7%). A low rate of severe GVHD enables continued tapering of post-transplant immunosuppressive agents. This may have balanced the offset from other risk factors (T cell depletion, antigen mismatches, and use of ATG), and contributed to the observed incidence of EBV-LPD in our high-risk patient population when compared to other reports. 8, 12 Therapies for EBV-LPD have been widely explored, from supportive antiviral agents (acyclovir, interferon-␣, IG) to adoptive immunotherapy with EBV-specific cytotoxic T cell or donor leukocyte infusion. [21] [22] [23] [24] All our transplant recipients received prophylactic antiviral therapy upon admission and while they were receiving immunosuppressive agents. No study has shown that prophylactic antiviral therapy during the transplant course can reduce posttransplant EBV-LPD. After the diagnosis of EBV-LPD, all patients in our series continued to receive supportive antiviral therapies and decreased doses of immunosuppressive agents. Some patients received donor leukocyte infusions with CD3 + doses ranging from 0.5 × 10 5 to 5.91 × 10 7 /kg. Patient UPN 281 received the lowest dose of 0.5 × 10 5 for a pulmonary lesion and has been disease-free for 29 months. Of note, two patients who received pre-emptive DLI early post transplant to prevent primary disease relapse, later developed EBV-LPD (more than 15 months post transplant). One may speculate that the early administration of DLI may have actually delayed the development of EBV-LPD, but this protective effect was not sustained. The effective DLI dose for treatment was also difficult to determine in our cohort study since patients received a wide range of CD3 + cells at different times post BMT. The risk of developing GVHD with DLI was a concern especially if they were given early in the post-transplant period with HLA mismatched donors.
The new development of an anti-B cell monoclonal antibody has been shown to be effective in the treatment of some lymphomas, and has also appeared to be an attractive approach for the management of LPD. 25, 26 We have used Rituxan as part of the initial treatment in two patients with one showing a partial response. With such a small number of patients, It is impossible to draw any meaningful conclusion. However, its potential clinical efficacy in early detectable cases warrants further evaluation. Even though our study represents the largest single center experience in EBV-LPD using a mismatched, T celldepleted graft, we feel that the sample size still prevents us from carrying out a trend analysis in these risk factors. The other limiting factor in this study was the low rate of autopsy (around 10%). This has probably led to an underestimation of the actual incidence of EBV-LPD, in our observation. It was also interesting to note that UPN 307 received an EBV-negative graft and developed LPD 4 months post transplant. It was not clear to us if the donor later converted to EBV positivity, shortly after the marrow donation.
In conclusion, alternative donors combined with graft manipulation can provide an immediate treatment option beyond ethnic and time constraints for patients needing bone marrow transplantation. In this study, we observed a lower incidence of EBV-associated lymphoproliferative disorders than that reported, given that all patients received an intense immunosuppressive regimen for GVHD prophylaxis and despite the presence of all known high-risk factors. The pathogenesis of EBV-LPD is thought to be multifactorial and not well understood. We believe that prevention and early control of GVHD play a significant contributing role in diminishing EBV-LPD since this minimizes prolonged administration of immunosuppressive agents. Supportive care (antiviral, IG) and/or adoptive immunotherapy (withdraw of immunosuppressive agents, anti-B cell MAb, non-specific and/or EBV-specific lymphocyte infusion) should be integrated into the treatment regimen of this aggressive and often fatal disease.
